Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small cell carcinoma (non-otherwise specified)

This is a summary of the recommendations on management options for people with non-squamous and non-small cell carcinoma from the NICE guideline on lung cancer. See www.nice.org.uk/guidance/NGXX, and see technology appraisals for information on eligibility, patient access schemes and more.

© NICE 2018. All rights reserved. Subject to Notice of rights.


No gene mutation or fusion protein and PD-L1 <50%

- EGFR positive
  - Afatinib (TA310) or Erlotinib (TA258) or Gefitinib (TA192)
  - Ceritinib (TA500) or Alectinib (TA310)
  - Crizotinib (TA529)

- ALK positive
  - Crizotinib (TA406) or Ceritinib (TA395)

- ROS-1 positive
  - Crizotinib (TA422)

- PD-L1 ≥50%
  - Pembrolizumab (TA531)

- T790M positive?
  - Yes
    - Osimertinib (TA416)
  - No
    - Platinum doublet chemotherapy

Platinum doublet chemotherapy*
- Pemetrexed+Cisplatin (TA181)
- Pemetrexed+Carboplatin*
- Pemetrexed maintenance (TA402 or TA190)

Atezolizumab (no PD-L1 expression needed) (TA520)
- Nivolumab (if PD-L1 >1%) (TA484)
- Pembrolizumab (if PD-L1 >1%) (TA428)

Docetaxel +/- Nintedanib (TA347)

No gene mutation or fusion protein and PD-L1 <50%

- EGFR positive
  - Afatinib (TA310) or Erlotinib (TA258) or Gefitinib (TA192)
  - Ceritinib (TA500)
  - Crizotinib (TA529)

- ALK positive
  - Alectinib (TA310)
  - Crizotinib (TA406)
  - Ceritinib (TA395)

- ROS-1 positive
  - Crizotinib (TA422)

- PD-L1 ≥50%
  - Pembrolizumab (TA531)

- T790M positive?
  - Yes
    - Osimertinib (TA416)
  - No
    - Platinum doublet chemotherapy

Platinum doublet chemotherapy*
- Pemetrexed+Cisplatin (TA181)
- Pemetrexed+Carboplatin*
- Pemetrexed maintenance (TA402 or TA190)

Atezolizumab (no PD-L1 expression needed) (TA520)
- Nivolumab (if PD-L1 >1%) (TA484)
- Pembrolizumab (if PD-L1 >1%) (TA428)

Docetaxel +/- Nintedanib (TA347)

ROS-1 positive
- Ceritinib (TA500)
- Crizotinib (TA529)

ALK positive
- Afatinib (TA310)
- Erlotinib (TA258)
- Gefitinib (TA192)

EGFR positive
- Afatinib (TA310)
- Erlotinib (TA258)
- Gefitinib (TA192)

Crizotinib (TA406)
- Ceritinib (TA395)

PD-L1 ≥50%
- Pembrolizumab (TA531)

Disease progression
- Cancer Drugs Fund

This combination/some of these combinations of drugs do not have a UK marketing authorisation for this indication

* This combination/some of these combinations of drugs do not have a UK marketing authorisation for this indication.


© NICE 2018. All rights reserved. Subject to Notice of rights.

T790M positive?